These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38780262)

  • 1. Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
    Moeck G; Gasink LB; Mendes RE; Woosley LN; Dorr M; Chen H; Wagenlehner FM; Henkel T; McGovern PC
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0023624. PubMed ID: 38780262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
    N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
    Lasko MJ; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain.
    Hernández-García M; García-Castillo M; Nieto-Torres M; Bou G; Ocampo-Sosa A; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Oliver A; Ruiz-Garbajosa P; Cantón R
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):279-296. PubMed ID: 38041722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
    Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?
    Bassetti M; Giacobbe DR
    Med; 2024 May; 5(5):380-382. PubMed ID: 38733970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
    Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
    Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli.
    Roach EJ; Uehara T; Daigle DM; Six DA; Khursigara CM
    Microbiol Spectr; 2021 Oct; 9(2):e0091821. PubMed ID: 34494877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in
    Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
    Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP
    J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
    Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in
    Kloezen W; Melchers RJ; Georgiou PC; Mouton JW; Meletiadis J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.